Patent · US Active

Modulation of Lnc05 expression

US11033570B2 · kind B2 · utility

2Cited by
188References
13Claims
0Family size

Assignees

Inventors

Key dates

Filing dateDec 1, 2017
Grant dateJun 15, 2021
Priority date
Expiry dateDec 1, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2310/341
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are methods, compounds, and compositions for reducing expression of Inc05 in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a cancer in an individual.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.